I-Mab (IMAB) - Total Assets
Based on the latest financial reports, I-Mab (IMAB) holds total assets worth $277.41 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check IMAB total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
I-Mab - Total Assets Trend (2017–2024)
This chart illustrates how I-Mab's total assets have evolved over time, based on quarterly financial data. Explore I-Mab (IMAB) long-term investment share to see how much of total assets are deployed in long-term investments.
I-Mab - Asset Composition Analysis
Current Asset Composition (December 2024)
I-Mab's total assets of $277.41 Million consist of 83.1% current assets and 16.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.1% |
| Accounts Receivable | $1.17 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how I-Mab's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see I-Mab (IMAB) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: I-Mab's current assets represent 83.1% of total assets in 2024, an increase from 67.5% in 2017.
- Cash Position: Cash and equivalents constituted 32.1% of total assets in 2024, up from 30.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
I-Mab Competitors by Total Assets
Key competitors of I-Mab based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
I-Mab - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.47 | 15.99 | 9.28 |
| Quick Ratio | 14.47 | 15.99 | 9.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $216.68 Million | $176.44 Million | $4.77 Billion |
I-Mab - Advanced Valuation Insights
This section examines the relationship between I-Mab's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.76 |
| Latest Market Cap to Assets Ratio | 2.15 |
| Asset Growth Rate (YoY) | -91.9% |
| Total Assets | $212.68 Million |
| Market Capitalization | $456.45 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values I-Mab's assets at a significant premium (2.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: I-Mab's assets decreased by 91.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for I-Mab (2017–2024)
The table below shows the annual total assets of I-Mab from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $212.68 Million | -91.86% |
| 2023-12-31 | $2.61 Billion | -35.86% |
| 2022-12-31 | $4.07 Billion | -27.64% |
| 2021-12-31 | $5.63 Billion | -11.12% |
| 2020-12-31 | $6.33 Billion | +264.52% |
| 2019-12-31 | $1.74 Billion | -26.87% |
| 2018-12-31 | $2.38 Billion | +131.72% |
| 2017-12-31 | $1.03 Billion | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more